# US 2024/0189312 A1 · Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189312 A1
- Document ID: US20240189312A1
- Status: Published application
- Kind: A1
- Application number: 18/527,676
- Filed: 2023-12-04
- Published: 2024-06-13
- Earliest claimed: 2022-12-02
- Assignees: Morehouse School of Medicine
- Applicants: Morehouse School of Medicine
- Inventors: Tiandong LENG
- Web page: https://patentgrep.com/patent/US20240189312A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions that inhibit CYP46A pathways are provided for the prevention and treatment of neurodegenerative disease and brain injury, including i.e. Alzheimer's disease, tanopathies, cerebral ischemia and/or brain trauma. Compositions of the application are voriconazole, or analog compounds of voriconazole, or variants of voriconazole with a generic substitution in its chemical structure.

## Claims

### Claim 1

A method of treating a neurodegenerative disease in a subject in need thereof comprising
administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising voriconazole, or analog compound of voriconazole, or variant of voriconazole with a generic substitution in its chemical structure, and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is one or more selected from the group consisting of Alzheimer's disease and tauopathies.

### Claim 3 (depends on 1)

The method of claim 1, wherein the voriconazole is packaged for delivery in a titratable dosage form.

### Claim 4 (depends on 1)

The method of claim 1, wherein the voriconazole is packaged such that delivery is targeted to an area selected from the group consisting of: sublingual; buccal; parenteral; oral; rectal, nasal; and the pulmonary system.

### Claim 5 (depends on 1)

The method of claim 1, wherein the voriconazole is in the form selected from the group consisting of: gel; gel spray; tablet; liquid; capsule and for vaporization.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering a secondary neuroprotective therapeutic or adjunctive therapeutic agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the secondary neuroprotective therapeutic agent or other adjunctive therapeutic agent is an CYP46A1 inhibiting agent selective for a glutamate receptor, an alkalinizing agent, an anticoagulant, tissue plasminogen activator, aspirin, or an anti-platelet agent.

### Claim 8 (depends on 6)

The method of claim 6, wherein the secondary neuroprotective therapeutic or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said voriconazole,

### Claim 9 (depends on 6)

The method of claim 6, wherein the secondary neuroprotective therapeutic or adjunctive therapeutic agent is administered to said subject by a different method than the administration of the voriconazole.

### Claim 10 (depends on 2)

The method of claim 2, wherein the neurodegenerative disease is Alzheimer's disease.

### Claim 11 (depends on 1)

The method of claim 1, wherein said voriconazole is administered to said subject nasally, intrathecally, and/or epidurally.

### Claim 12

A method of treating Alzheimer's disease in a subject in need thereof comprising
administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising voriconazole, or analog compound of voriconazole, or variant of voriconazole with a generic substitution in its chemical structure, and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Alzheimer's disease is at a stage of pre-clinical Alzheimer's disease.

### Claim 14 (depends on 12)

The method of claim 12, wherein the voriconazole is packaged for delivery in a titratable dosage form.

### Claim 15 (depends on 12)

The method of claim 12, wherein the voriconazole is packaged such that delivery is targeted to an area selected from the group consisting of: sublingual; buccal; parenteral; oral; rectal, nasal; and the pulmonary system.

### Claim 16

A method of treating acute brain injury in a subject in need thereof, comprising:
administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising voriconazole, or analog compound of voriconazole, or variant of voriconazole with a generic substitution in its chemical structure, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 16)

The method of claim 16, wherein the voriconazole is packaged for delivery in a titratable dosage form.

### Claim 18 (depends on 16)

The method of claim 16 wherein said voriconazole is administered to said subject nasally, orally, and/or in liquid form.

### Claim 19 (depends on 16)

The method of claim 16, wherein the acute brain injury is cerebral ischemia.

### Claim 20 (depends on 16)

The method of claim 16, wherein the acute brain injury is brain trauma.
